Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond

ABSTRACT:

Simple Summary

Relapsed or refractory (r/r) lymphomas represent hard-to-treat cancers with dismal prognoses. Over the past few years, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have changed treatment paradigms in many malignancies, and are currently approved for Hodgkin lymphoma. Despite improvements in treatment outcomes and the implementation of combined modality approaches, outcomes in patients with r/r lymphomas remain suboptimal. Accumulating evidence suggests that under certain conditions, radiation may be delivered, in conjunction with checkpoint inhibitors or other small molecules, to augment efficacy. In this review, we discuss the interactions of novel therapies approved for lymphomas, mechanis

SUBMITTER: Perrone S 

PROVIDER: S-EPMC10216471 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature